22 results
8-K
EX-10.1
UNCY
Unicycive Therapeutics Inc
14 Mar 24
Unicycive Announces $50 Million Private Placement
4:28pm
8-K
EX-10.1
UNCY
Unicycive Therapeutics Inc
14 Mar 24
Entry into a Material Definitive Agreement
4:00pm
8-K
EX-10.1
UNCY
Unicycive Therapeutics Inc
10 Apr 23
Entry into a Material Definitive Agreement
6:16am
8-K
EX-10.2
UNCY
Unicycive Therapeutics Inc
6 Mar 23
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
5:02pm
8-K
EX-10.1
UNCY
Unicycive Therapeutics Inc
6 Mar 23
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
5:02pm
8-K
EX-10.1
tugz38g3w1
2 Feb 23
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
4:45pm
8-K
EX-10.1
t0xrvkdvf920y 3w
18 Jul 22
Expands and accelerates Renazorb opportunity in important markets for patients with hyperphosphatemia through local partner with deep domain expertise
4:15pm
S-1/A
EX-10.1
vx2tngig5ay7l4ym
7 Jun 21
IPO registration (amended)
7:01am
S-1/A
EX-10.5
t7aui
7 Jun 21
IPO registration (amended)
7:01am
S-1/A
EX-10.4
t74pcjm 7qwr2g11eu
7 Jun 21
IPO registration (amended)
7:01am
S-1/A
EX-10.2
qn6qosqj8 6b
7 Jun 21
IPO registration (amended)
7:01am
S-1/A
EX-10.6
joe rp10b5gv87m539ra
7 Jun 21
IPO registration (amended)
7:01am
S-1
EX-10.10
s8df83avavg6mvs4u
21 May 21
IPO registration
4:07pm
S-1
EX-10.7
50elvdke11x3y09yd2v
21 May 21
IPO registration
4:07pm
S-1
EX-10.3
6bv1jktq10a25vxukv
21 May 21
IPO registration
4:07pm
S-1
EX-10.8
q5aq00g0
21 May 21
IPO registration
4:07pm
S-1
EX-10.9
pacio5q
21 May 21
IPO registration
4:07pm
DRS/A
EX-10.1
qwl32d 9qnfksfddeo
29 Apr 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.2
1tux8ee9s5di3bhc2ny
29 Apr 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.4
iuti5
29 Apr 21
Draft registration statement (amended)
12:00am